BACKGROUND: Increasing the interval from completion of neoadjuvant therapy to surgery beyond 8 weeks is associated with increased response of rectal cancer to neoadjuvant therapy. However, reports are conflicting on whether extending the time to surgery is associated with increased perioperative morbidity. METHODS: Patients who presented with a tumor within 15 cm of the anal verge in 2009-2015 were grouped according to the interval between completion of neoadjuvant therapy and surgery: < 8 weeks, 8-12 weeks, and 12-16 weeks. RESULTS: Among 607 patients, the surgery was performed at < 8 weeks in 317 patients, 8-12 weeks in 229 patients, and 12-16 weeks in 61 patients. Patients who underwent surgery at 8-12 weeks and patients who underwent surgery at < 8 weeks had comparable rates of complications (37% and 44%, respectively). Univariable analysis identified male sex, earlier date of diagnosis, tumor location within 5 cm of the anal verge, open operative approach, abdominoperineal resection, and use of neoadjuvant chemoradiotherapy alone to be associated with higher rates of complications. In multivariable analysis, male sex, tumor location within 5 cm of the anal verge, open operative approach, and neoadjuvant chemoradiotherapy administered alone were independently associated with the presence of a complication. The interval between neoadjuvant therapy and surgery was not an independent predictor of postoperative complications. CONCLUSIONS: Delaying surgery beyond 8 weeks from completion of neoadjuvant therapy does not appear to increase surgical morbidity in rectal cancer patients.
BACKGROUND: Increasing the interval from completion of neoadjuvant therapy to surgery beyond 8 weeks is associated with increased response of rectal cancer to neoadjuvant therapy. However, reports are conflicting on whether extending the time to surgery is associated with increased perioperative morbidity. METHODS:Patients who presented with a tumor within 15 cm of the anal verge in 2009-2015 were grouped according to the interval between completion of neoadjuvant therapy and surgery: < 8 weeks, 8-12 weeks, and 12-16 weeks. RESULTS: Among 607 patients, the surgery was performed at < 8 weeks in 317 patients, 8-12 weeks in 229 patients, and 12-16 weeks in 61 patients. Patients who underwent surgery at 8-12 weeks and patients who underwent surgery at < 8 weeks had comparable rates of complications (37% and 44%, respectively). Univariable analysis identified male sex, earlier date of diagnosis, tumor location within 5 cm of the anal verge, open operative approach, abdominoperineal resection, and use of neoadjuvant chemoradiotherapy alone to be associated with higher rates of complications. In multivariable analysis, male sex, tumor location within 5 cm of the anal verge, open operative approach, and neoadjuvant chemoradiotherapy administered alone were independently associated with the presence of a complication. The interval between neoadjuvant therapy and surgery was not an independent predictor of postoperative complications. CONCLUSIONS: Delaying surgery beyond 8 weeks from completion of neoadjuvant therapy does not appear to increase surgical morbidity in rectal cancerpatients.
Authors: Peirong Ding; David Liska; Peter Tang; Jinru Shia; Leonard Saltz; Karyn Goodman; Robert J Downey; Garrett M Nash; Larissa K Temple; Philip B Paty; José G Guillem; W Douglas Wong; Martin R Weiser Journal: Ann Surg Date: 2012-07 Impact factor: 12.969
Authors: Y Francois; C J Nemoz; J Baulieux; J Vignal; J P Grandjean; C Partensky; J C Souquet; P Adeleine; J P Gerard Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling Journal: Lancet Date: 2010-03-20 Impact factor: 79.321
Authors: D A M Sloothaak; D E Geijsen; N J van Leersum; C J A Punt; C J Buskens; W A Bemelman; P J Tanis Journal: Br J Surg Date: 2013-03-27 Impact factor: 6.939
Authors: Matthew F Kalady; Luiz Felipe de Campos-Lobato; Luca Stocchi; Daniel P Geisler; David Dietz; Ian C Lavery; Victor W Fazio Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Mary Kay Washington; Jordan Berlin; Philip Branton; Lawrence J Burgart; David K Carter; Patrick L Fitzgibbons; Kevin Halling; Wendy Frankel; John Jessup; Sanjay Kakar; Bruce Minsky; Raouf Nakhleh; Carolyn C Compton Journal: Arch Pathol Lab Med Date: 2009-10 Impact factor: 5.534
Authors: Seth I Felder; Sebastian Feuerlein; Arthur Parsee; Iman Imanirad; Julian Sanchez; Sophie Dessureault; Richard Kim; Sarah Hoffe; Jessica Frakes; James Costello Journal: Abdom Radiol (NY) Date: 2020-10-28
Authors: Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery Journal: J Gastrointest Surg Date: 2020-06-30 Impact factor: 3.452